huge sums for smaller innovators. For example, last summer, Amgen upped its offer to buy cancer drug maker Onyx Pharmaceuticals from $9.3 billion to $9.7 billion. Such deals — along with generally healthy balance sheets and access to capital among life sciences companies
sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER:VRTX] Onyx Pharmaceuticals , has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been
with its internal prospects last quarter when it decided to make the $10 billion debt-funded acquisition of Onyx Pharmaceuticals ONXX (rating: SUS, no moat). This acquisition will boost Amgen's top-line growth by nearly 200 basis points
Aug 26 (Reuters) - Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood...
After several weeks of media speculation, Amgen finally announced the acquisition of Onyx Pharmaceuticals for $125 per share, valuing the company at $10.4 billion (or $9.7 billion net of cash). As we stated previously, we
NEW YORK (Reuters) - Amgen Inc, the drugmaker in advanced discussions to buy Onyx Pharmaceuticals Inc, has asked Onyx for some of the data from an ongoing trial on the company's new blood cancer...
(Adds Onyx Pharmaceuticals , Telediffusion de France, TPG Capital and others)
(Reuters) - Some options traders appeared to have scored a win with well-timed bullish bets on Onyx Pharmaceuticals before a rival made an unsolicited bid for the cancer drug maker.
Onyx ONXX confirmed on Sunday that it had received an unsolicited bid from Amgen AMGN of $120 per share, a 38% premium to Friday's close
pipeline potential, therapeutic area attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx ONXX , Regeneron REGN, Incyte INCY, Biomarin BMRN, and Seattle Genetics SGEN. Valeant VRX made the biggest acquisition splash